Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29092550 | 0.91 | MTNR1A (0.57) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL5669243 | 0.83 | TSHR (0.59) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2224069 | 0.82 | CA12 (0.73) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL9781928 | 0.81 | KMT2A (0.56) | MEN1KMT2ACA12CA1CA2 | |
| Water SCHEMBL11279885 | 0.81 | CA12 (0.71) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL5723848 | 0.80 | MTNR1A (0.84) | SMN1; SMN2MTNR1AMTNR1BKDM4EALDH1A1 | |
| SCHEMBL18183526 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2MTNR1AMTNR1BKDM4E | |
| SCHEMBL14812349 | 0.78 | MTNR1A (0.60) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL10696558 | 0.78 | HTR2A (0.62) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL6376716 | 0.78 | MEN1 (0.79) | MEN1KMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398751-A1 | Methods of treating or reducing symptoms of stimulant dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and glutamate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240398750-A1 | Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators. | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240325342-A1 | Methods of treating or reducing symptoms of opiate dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and opiate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| US-20240299341-A1 | Methods of treating or reducing symptoms of nicotine dependency (addiction) such as tobacco-use (smoking, vaping, sublingual, oral) and/or tobacco smoking cessation via combination therapy with allosteric modulators and phenethylamines. | HELDRETH JR DAVID ALAN (US) | 2024-09-12 | — | — | US | claimed |
| US-20240269107-A1 | Methods of treating or reducing symptoms of brain cancer such as glioma and glioblastoma via combination therapy with allosteric modulators and phenethylamines. | HELDRETH JR DAVID ALAN (US) | 2024-08-15 | — | — | US | claimed |
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. | 2025-05-22 | — | — | US | disclosed |
| US-20240245632-A1 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | JOURNEY COLAB CORP. | 2024-07-25 | — | — | US | disclosed |
| CN-116916903-A | Effects of Moschserin and Moschserin analogs (SCALINES) on adjuvant psychotherapy | 巴塞尔大学医院 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023164178-A2 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164178-A2 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2022251690-A1 | MESCALINE FOR THE TREATMENT OF SUBSTANCE USE DISORDERS | JOURNEY COLAB CORP. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-6829540-B1 | Data processing, drug screening using immobilized artificial membrane chromatographic substrates in high pressure liquid chromatographic systems using aqueous mobile phases | PURDUE RESEARCH FOUNDATION | 2004-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245632-A1 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | SLC6A12, SLC6A3, TPMT | MEN1 1441/4885KMT2A 213/4885SMN1; SMN2 576/4885 |
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | IL4I1, ME3, LIG3 | MEN1 179/4885KMT2A 786/4885SMN1; SMN2 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.